Manejo de la urticaria crónica espontánea en la práctica clínica diaria siguiendo las indicaciones de la guía EAACI/GA(2)LEN/EDF/WAO / Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines

Introducción: La urticaria crónica espontánea es una enfermedad prevalente, de difícil manejo terapéutico y con una importante repercusión en la calidad de vida del paciente. Objetivo: Describir las características epidemiológicas, clínicas y la respuesta terapéutica de los pacientes con urticaria crónica espontánea actuando según la guía de consenso EAACI/GA(2)LEN/EDF/WAO. Material y método: Estudio descriptivo transversal que incluyó todos los pacientes con urticaria crónica espontánea visitados en una consulta específica de alergia cutánea de un servicio de dermatología de un hospital terciario en España desde julio de 2011 hasta julio de 2015. Resultados: Cien pacientes con urticaria crónica espontánea participaron en el estudio. El 43% asociaba una urticaria inducible. El 40% asociaba angioedema. El 53% de los pacientes tomaba antiinflamatorios no esteroideos en el momento del diagnóstico. Todos los pacientes fueron tratados con antihistamínicos-H1 de segunda generación, pero solo un 18% se controló con dosis licenciadas, mientras que el aumento hasta 4 veces la dosis logró controlar el 74% de los pacientes. Los pacientes con angioedema requirieron dosis mayores de antihistamínicos-H1 de segunda generación que los pacientes sin angioedema para el control de la urticaria crónica espontánea, siendo el angioedema un factor asociado a falta de respuesta a tratamiento con antihistamínicos-H1 de segunda generación (OR 6,1%, p < 0,001). Uno de cada 4 pacientes no respondió a antihistamínicos-H1 de segunda generación y requirió omalizumab o ciclosporina para su control. Conclusiones: El control de la urticaria crónica espontánea precisa de la utilización de antihistamínicos-H1 de segunda generación a dosis más altas de las licenciadas en la mayoría de los casos. El angioedema se asocia a falta de respuesta al tratamiento con antihistamínicos. El omalizumab y la ciclosporina logran controlar los casos refractarios. La evitación de antiinflamatorios no esteroideos no es una práctica habitual en los pacientes con urticaria crónica espontánea (AU)

Introduction: Chronic spontaneous urticaria is a prevalent and difficult-to-treat condition that has a very negative impact on patient quality of life. Objective: To describe the epidemiological and clinical characteristics of patients presenting with chronic spontaneous urticaria and the response to treatment administered according to the EAACI/GA(2)LEN/EDF/WAO consensus guideline. Material and method: Descriptive cross-sectional study of all the patients with chronic spontaneous urticaria who consulted a skin allergy unit in the dermatology department of a tertiary hospital in Spain between July 2011 and July 2015. Results: The study included 100 patients with chronic spontaneous urticaria; inducible urticaria was present in 43% of cases, and angioedema in 40%. On diagnosis, 53% of patients were taking nonsteroidal anti-inflammatory drugs. All patients were treated with second generation H1-antihistamines, but the standard dose was sufficient in only 18% of cases. Higher doses (up to 4 times the standard dose) achieved control of the urticaria in 74% of the patients studied. Higher doses of second generation H1-antihistamines were required to control the condition in patients with angioedema, and the presence of angioedema was associated with a lack of response to treatment with these drugs (OR, 6.1%; P < .001). One in 4 patients failed to respond to second generation H1-antihistamines and required treatment with omalizumab or ciclosporin to control their condition. Conclusions: Doses of H1-antihistamines higher than the standard dose are required in most cases to achieve control of chronic spontaneous urticaria. Angioedema is associated with failure to respond to treatment with antihistamines. In refractory cases, control of the condition can be achieved with omalizumab or ciclosporin. Patients with chronic spontaneous urticaria do not generally avoid the use of nonsteroidal anti-inflammatory agents (AU)

Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines. / Manejo de la urticaria crónica espontánea en la práctica clínica diaria siguiendo las indicaciones de la guía EAACI/GA(2)LEN/EDF/WAO.

INTRODUCTION: Chronic spontaneous urticaria is a prevalent and difficult-to-treat condition that has a very negative impact on patient quality of life. OBJECTIVE: To describe the epidemiological and clinical characteristics of patients presenting with chronic spontaneous urticaria and the response to treatment administered according to the EAACI/GA(2)LEN/EDF/WAO consensus guideline. MATERIAL AND METHOD: Descriptive cross-sectional study of all the patients with chronic spontaneous urticaria who consulted a skin allergy unit in the dermatology department of a tertiary hospital in Spain between July 2011 and July 2015. RESULTS: The study included 100 patients with chronic spontaneous urticaria; inducible urticaria was present in 43% of cases, and angioedema in 40%. On diagnosis, 53% of patients were taking nonsteroidal anti-inflammatory drugs. All patients were treated with second generation H1-antihistamines, but the standard dose was sufficient in only 18% of cases. Higher doses (up to 4 times the standard dose) achieved control of the urticaria in 74% of the patients studied. Higher doses of second generation H1-antihistamines were required to control the condition in patients with angioedema, and the presence of angioedema was associated with a lack of response to treatment with these drugs (OR, 6.1%; P<.001). One in 4 patients failed to respond to second generation H1-antihistamines and required treatment with omalizumab or ciclosporin to control their condition. CONCLUSIONS: Doses of H1-antihistamines higher than the standard dose are required in most cases to achieve control of chronic spontaneous urticaria. Angioedema is associated with failure to respond to treatment with antihistamines. In refractory cases, control of the condition can be achieved with omalizumab or ciclosporin. Patients with chronic spontaneous urticaria do not generally avoid the use of nonsteroidal anti-inflammatory agents.

Assessment of subclinical atherosclerosis in hidradenitis suppurativa.

BACKGROUND: Patients with hidradenitis suppurativa (HS) have an increased prevalence of traditional cardiovascular risk factors. OBJECTIVE: Our aim was to investigate the association between subclinical atherosclerosis, detected by carotid ultrasound, and HS. METHODS: A prospective observation and analytical study assessing subclinical atherosclerosis using carotid ultrasound in patients with HS. RESULTS: A total of 62 HS patients and 62 matched controls were studied. Diabetes mellitus (22.6% vs. 6.5%, P = 0.020), hypertension (41.9% vs. 12.9%, P < 0.001) and metabolic syndrome (MetS) (38.7% vs. 8.1%, P < 0.001) were more common in HS patients. Elevated neutrophil-to-lymphocyte ratio (59.7% vs. 40.3%, P = 0.031), high-sensitivity C-reactive protein (61.1 vs. 29.0%, P < 0.001) and erythrocyte sedimentation rate (46.8% vs. 9.7%, P < 0.001) were more frequent in patients with HS. Subclinical atherosclerosis was present in 30.6% of HS patients and in 16.1% of the controls subjects (P = 0.06). After a logistic regression analysis, elevated age was associated with the presence of subclinical atherosclerosis (P < 0.001), and HS showed a tendency towards this association [adjusted OR (95% CI) 3.8 (0.9-16.0), P = 0.066]. This association was statistically significant between patients 40 years and older [OR (95% CI) 4.9 (1.8-13.1)]. CONCLUSIONS: Our clinical results indicate that patients with HS have a higher prevalence of subclinical atherosclerosis than expected when correcting for traditional risk factors. The findings support the conclusions of previous epidemiological studies.